Harmony Biosciences Holdings (HRMY) Other Non-Current Liabilities (2019 - 2026)

Harmony Biosciences Holdings has reported Other Non-Current Liabilities for 8 years, with the latest figure at $5.3 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 211.17% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (up 211.17% YoY) and the FY2025 annual result came in at $5.6 million, up 188.55% from the prior year.
• Other Non-Current Liabilities fell to $5.3 million in Q1 2026 per HRMY's latest filing, from $5.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $5.6 million in Q4 2025 and troughed at $1.2 million in Q3 2025.
• A 5-year average of $2.5 million and a median of $2.1 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 270.4% in 2022, then tumbled 47.21% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $2.5 million in 2022, then fell by 15.57% to $2.1 million in 2023, then decreased by 7.68% to $1.9 million in 2024, then jumped by 188.55% to $5.6 million in 2025, then retreated by 5.29% to $5.3 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $5.3 million, $5.6 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.